Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNFα

Gene Therapy

Volumn 4, Issue 11, 1997, Pages 1181-1188

  Marr, R A ^a   Addison, C L ^a   Snider, D ^a   Muller, W J ^a   Gauldie, J ^a   Graham, F L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Adenovirus vector; Gene therapy; Immunotherapy; Membrane bound TNF; Tumour necrosis factor ; Tumour therapy

Indexed keywords

MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SPLEEN CELL; TRANSGENIC MOUSE; TUMOR REGRESSION;

ADENOVIRIDAE; ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0030814849     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300528     Document Type: Article

References (41)

1. Carswell EA et al. An endotoxin induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA 1975; 72: 3666-3670.
2. Fiers W. Tumour necrosis factor Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991; 285: 199-212.
3. Balkwill FR. Tumour necrosis factor and cancer. Prog Growth Fact Res 1992; 4: 121-137.
4. Tracey KJ, Cerami A. Tumour necrosis factor: a pleiotropic cytokine and therapeutic target. Ann Rev Med 1994; 45: 491-503.
5. Sarraf CE. Tumour necrosis factor and cell death in tumours (review). Int J Oncol 1994; 5: 1333-1339.
6. Balkwill FR, Naylor MS, Malik S. Tumour necrosis factor as an anticancer agent. Eur J Cancer 1990; 26: 641-644.
7. Prober JS. Effects of tumour necrosis factor and related cytokines on vascular endothelial cells. In: Bock G, Marsh J (eds). Tumour Necrosis Factor and Related Cytotoxins. Wiley: Chichester, 1984 (Ciba Foundation Symposium 131), pp 170-185.
8. Clauss M, Ryan J, Stern D. Modulation of endothelial cell haemostatic properties by TNF: Insights into the role of endothelium in the host response to inflammatory stimuli. In: Beutler D (ed). Tumour Necrosis Factors The Molecules and their Emerging Role in Medicine. Raven Press: New York, 1992, pp 49-64.
9. Denekamp J. Review article angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181-196.
10. Paleolog EM, Delasalle SAJ, Buurman WA, Feldmann M. Functional activities of receptors for tumour necrosis factor-α on human vascular endothelial cells. Blood 1994; 84: 2578-2590.
11. Palladino MA Jr et al. Characterization of the antitumour activities of human tumour necrosis factor alpha and the comparison with other cytokines: induction of tumour-specific immunity. J Immunol 1987; 138: 4023-4032.
12. Treper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumour cells. Hum Gene Ther 1994; 5: 153-164.
13. Marincola FM et al. Treatment of established lung metastases with tumour-infiltrating lymphocytes derived from a poorly immunogenic tumour engineered to secrete human TNF-α. J Immunol 1994; 152: 3500-3513.
14. Tracey KJ et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-474.
15. Tracey KJ. TNF and Mae West or death from too much of a good thing. Lancet 1995; 345: 75-76.
16. Bramson JL et al. Direct intratumoural injection of an adenovirus expressing interleukin-12 induces regression and long lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7: 1995-2002.
17. Engelhardt JF et al. Direct transfer of a human CFTR into human bronchial epithelia of xenografts with El-deleted adenoviruses. Nat Genet 1993; 4: 27-34.
18. Guzman RJ et al. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res 1993; 73: 1202-1207.
19. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyoma virus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992, 12 954-961.
20. Decoster E et al. Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor. J Biol Chem 1995; 270: 18473-18478.
21. Addison CL et al. Intra-tumoural injection of an adenovirus expressing interleukin-2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995; 92: 8522-8526.
22. Bramson J et al. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther 1996; 7: 333-342.
23. Addison CL, Gauldie J, Muller WJ, Graham FL. An adenoviral vector expressing interleukin-4 modulates tumorigenicity and induces regression in a murine breast cancer model. Int J Oncol 1995; 7: 1253-1260.
24. Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity does not prevent regression following intratumoural administration of a vector expressing IL-12 but inhibits virus dissemination Gene Therapy 1997; 4: 1069-1076.
25. Karp SE et al. In vivo activity of tumour necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumours. J Immunol 1992; 149: 2076-2081.
26. Lewis M et al. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific Proc Natl Acad Sci USA 1991; 88: 2830-2834
27. Ranges GE et al. Tumor necrosis factor-α as a proliferative signal for an IL-2 dependent T cell line: strict species specificity of action. J Immunol 1989; 142: 1203-1208.
28. Tartaglia LA et al. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 1991; 88: 9292-9296
29. Bluethmann H et al. Establishment of the role of IL-6 and TNF receptor 1 using gene knockout mice. J Leukocyte Biol 1994; 56: 565-570.
30. Erickson SL et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994; 372: 560-563.
31. Sheehan KCF et al. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med 1995; 181: 607-617
32. Vandenabeele P et al. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J Exp Med 1992; 176: 1015-1024.
33. Ryffel B, Mihatsch MJ. TNF receptor distribution in human tissues. Int Rev Exp Pathol 1993; 34B: 149-156.
34. Trentin L et al. Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor. Br J Cancer 1995; 71: 240-245
35. Grell M et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumour necrosis factor receptor. Cell 1995; 83: 793-802.
36. + T cell clones provides a costimulatory signal for human B cell activation. J Exp Med 1993; 177: 1575-1585.
37. Perez C et al. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990; 63: 251-258.
38. Graham FL, Smiley J, Russel WC, Nairn R. Characterization of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-72.
39. Addison CL, Hitt M, Kunsken D, Graham FL Comparison of the human versus murine cytomegalovirus immediate-early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 1997; 78: 1653-1661.
40. Hitt M et al. Techniques for human adenovirus vector construction and characterization. In: Adolph KW (ed). Viral Gene Techniques Methods in Molecular Genetics. Academic Press: San Diego, 1995, Vol. 7, pp 13-30.
41. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.